Brief: Nykode Presents Additional Immunogenicity Data From VB-C-03 Trial
April 20 (Reuters) - Nykode Therapeutics ASA NYKD.OL: PRESENTS VB-C-03 TRIAL DATA SHOWING 100% IMMUNOGENICITY IN 6 AND 9 MG DOSE GROUPS ALL PATIENTS IN 6 AND 9 MG DOSE GROUPS SHOW HPV16-SPECIFIC IMMUNE RESPONSES IMMUNE RESPONSES RAPID AND DURABLE, PERSISTING TO END-OF-TREATMENT VB-C-03 TRIAL DEMONSTRATED CONFIRMED OBJECTIVE RESPONSE RATE OF 38.5% Source text: ID:nObir2hCha Further company coverage: NYKD.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026